0
0
The coronavirus pandemic still has us in its grip: new mutations, some extremely aggressive, are constantly being discovered. But now there is some good news: A new vaccine has been approved and should work even better and longer than the previous ones.
Even more potent than the one from BionTech: vaccine from Arcturus Therapeutics approved
In many parts of Europe, the vaccine from Biontech is still predominantly used. The recommendation is at least three vaccine doses. After a few months, a fourth vaccination or booster is also recommended for people over 60 and from so-called risk groups and employees in hospitals and care facilities.
This may soon come to an end. BILD and other news agencies reported that Japan has become the first country to approve the ARCT-154 vaccine from Arcturus Therapeutics (USA/Vietnam) for adults! This vaccine promises a more effective and, most importantly, longer-lasting immunization.
There are many advantages compared to previous vaccines, but also a disadvantage
The advantages: It is a so-called self-amplifying vaccine. This means the mRNA it contains copies itself by linking to specific genes. This means a significantly lower dose is required to achieve a high (and longer-lasting) antibody level.
In addition, the new vaccine can also be transported as a freeze-dried powder and even stored at room temperature. In contrast to Biontech and Moderna vaccines, it does not need to be refrigerated.
Nevertheless, there is a catch, even if the vaccine is approved in the near future: ARCT-154 protects longer and better. However, more people complain of side effects or vaccination reactions, usually more severe than with the other boosters.
– source: gentside.de/picture: pixabay.com
